Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 12/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 13/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 10/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 10/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
| ▸ | VEGFA | P15692 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL315053 | 0.97 | PDE4A (0.48) | PDE4APDE4BPDE4CPDE4DPOLB | |
| SCHEMBL12486463 | 0.93 | PDE4A (0.40) | PDE4APDE4BPDE4CPDE4DPOLB | |
| SCHEMBL2887418 | 0.90 | PDE4A (0.44) | PDE4APDE4BPDE4CPDE4DPOLB | |
| SCHEMBL17710554 | 0.89 | CSNK2A1 (0.33) | PDE4A | |
| SCHEMBL8492806 | 0.88 | PDE4A (0.43) | PDE4APDE4BPDE4CPDE4DPOLB | |
| SCHEMBL12486421 | 0.86 | PDE4A (0.36) | PDE4APDE4BPDE4CPDE4DPOLB | |
| SCHEMBL2887724 | 0.85 | CSNK2A1 (0.37) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL8594006 | 0.80 | PDE4D (0.48) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2483005 | 0.79 | HTR1A (0.43) | PDE4B | |
| SCHEMBL2104303 | 0.77 | CSNK2A1 (0.44) | PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202880-B2 | 3-hydroxy-6-phenylphenanthridines as PDE4 inhibitors | NYCOMED GMBH (DE) | 2012-06-19 | — | — | US | disclosed |
| US-7776893-B2 | Use of PDE4 inhibitors for the treatment of diabetes mellitus | NYCOMED GMBH (DE) | 2010-08-17 | — | — | US | disclosed |
| US-7632844-B2 | 2-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors | NYCOMED GMBH (DE) | 2009-12-15 | — | — | US | disclosed |
| US-20090170892-A1 | 3-Hydroxy-6-phenylphenanthridines as pde4 inhibitors | NYCOMED GMBH (DE) | 2009-07-02 | — | — | US | disclosed |
| US-20080319067-A1 | 2-Hydroxy-6-phenylphenanthridines as PDE-4 inhibitors | NYCOMED GMBH | 2008-12-25 | — | — | US | disclosed |
| US-7423046-B2 | 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors | NYCOMED GMBH (DE) | 2008-09-09 | — | — | US | disclosed |
| US-7329676-B2 | 2-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors | NYCOMED GMBH (DE) | 2008-02-12 | — | — | US | disclosed |
| US-20070259909-A1 | Novel Difluoroethoxy-Substituted Hydroxy-6-Phenylphenanthridines and Their Use as Pde4 Inhibitors | ALTANA PHARMA AG (DE) | 2007-11-08 | — | — | US | disclosed |
| EP-1536798-B1 | 3-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS | ALTANA PHARMA AG (DE) | 2007-02-07 | — | — | EP | disclosed |
| EP-1539164-B1 | 2-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS | ALTANA PHARMA AG (DE) | 2006-12-20 | — | — | EP | disclosed |
| US-20050239818-A1 | 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors | ALANA PHARMA AG (DE) | 2005-10-27 | — | — | US | disclosed |
| WO-2005085203-A1 | NOVEL DIFLUOROETHOXY-SUBSTITUTED HYDROXY-6-PHENYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | ALTANA PHARMA AG (DE) | 2005-09-15 | — | — | WO | disclosed |
| EP-1539164-A1 | 2-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS | ALTANA Pharma AG (DE) | 2005-06-15 | — | — | EP | disclosed |
| EP-1536798-A1 | 3-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS | ALTANA Pharma AG (DE) | 2005-06-08 | — | — | EP | disclosed |
| WO-2005023253-A1 | USE OF PDE4 INHIBITORS FOR THE TREATMENT OF DIABETES MELLITUS | ALTANA PHARMA AG (DE) | 2005-03-17 | — | — | WO | disclosed |
| WO-2004019945-A1 | 3-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS | ALTANA PHARMA AG (DE) | 2004-03-11 | — | — | WO | disclosed |
| WO-2004019944-A1 | 2-HYDROXY-6-PHENYLPHENANTHRIDINES AS PDE-4 INHIBITORS | ALTANA PHARMA AG (DE) | 2004-03-11 | — | — | WO | disclosed |
| US-6476025-B1 | Phenylphennanthridines with PDE-IV inhibiting activity | ALTANA PHARMA AG (DE) | 2002-11-05 | — | — | US | disclosed |
| EP-1147089-A1 | PHENYLPHENANTHRIDINES WITH PDE-IV INHIBITING ACTIVITY | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000042020-A1 | PHENYLPHENANTHRIDINES WITH PDE-IV INHIBITING ACTIVITY | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259909-A1 | Novel Difluoroethoxy-Substituted Hydroxy-6-Phenylphenanthridines and Their Use as Pde4 Inhibitors | PDE4A, PDE4B, PDE4D | PDE4A 1/4885PDE4B 2/4885PDE4C 4/4885 |
| US-20080319067-A1 | 2-Hydroxy-6-phenylphenanthridines as PDE-4 inhibitors | PDE4A, PDE4B, PDE3A | PDE4A 1/4885PDE4B 2/4885PDE4C 6/4885 |
| US-20050239818-A1 | 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors | PDE4A, PDE4B, PDE3A | PDE4A 1/4885PDE4B 2/4885PDE4C 6/4885 |
| US-20090170892-A1 | 3-Hydroxy-6-phenylphenanthridines as pde4 inhibitors | PDE4A, PDE4B, PDE3A | PDE4A 1/4885PDE4B 2/4885PDE4C 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.